CELZ Stock — Creative Medical Technology Holdings Inc

Creative Medical Technology Holdings Inc (CELZ)

Updated October 16, 2026.

CELZ is a Stock. Its deepest 1-year drawdown was 88.3%.

Creative Medical Technology Holdings is a commercial-stage biotechnology company developing novel cell and immunotherapies across multiple therapeutic areas, including treatments for erectile dysfunction, female sexual function, type 1 diabetes, chronic lower back pain, and premature ovarian failure. The company operates several product platforms including personalized immune therapy, allogeneic cell therapies, and regenerative stem cell procedures, with multiple programs in clinical development stages. The company does not currently have an established distribution schedule.

CELZ performance

Returns are updating. CELZ's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 88.3%.

CELZ key facts

Asset type

Stock

Asset class

Equity

Inception date

11/06/2015

Distribution frequency

None

Last close

$0.74 (as of 2026-10-16)

Market cap

$5,626,085

Average volume

168500.0

Payment date

02/03/2020

Beta

1.905

Payout ratio

0.0%

EPS

$-2.07

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CELZ risks and drawbacks

The deepest 1-year drawdown on record here is 88.3%.

Who may consider CELZ — and who may not

It is a weaker fit for investors who need monthly cash flow (CELZ does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CELZ

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions